相关实验视频
Updated: Jun 26, 2026
16:57
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
在没有运动并发症的情况下治疗帕金森病时,作为乐伏多巴的辅助剂的欧皮卡:一项随机临床试验
Joaquim J Ferreira1,2, Olivier Rascol3, Fabrizio Stocchi4
1IMM - Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade Lisboa, Lisbon, Portugal.
European journal of neurology
|January 10, 2025
概括
奥皮卡是一种甲基转移酶 (COMT) 抑制剂,在没有运动并发症的情况下改善了帕金森病患者的运动症状. 这种治疗耐受性很好,并且不会增加发展运动并发症的风险.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 运动障碍 运动障碍
背景情况:
- 甲基转移酶 (COMT) 抑制剂是管理帕金森病 (PD) 运动波动的标准.
- 在没有运动并发症的勒沃多巴治疗PD患者中,评估了欧皮卡对运动症状严重性的影响.
研究的目的:
- 评估奥皮卡作为辅助治疗在没有运动并发症的Levodopa治疗帕金森病患者的疗效和安全性.
- 用MDS-UPDRS-III尺度评估欧皮卡对运动症状严重性的影响.
主要方法:
- 这是一项为期24周的随机,双盲,安慰剂控制的研究.
- 355名没有运动并发症的Levodopa治疗患者接受了50毫克的Opicapone或安慰剂作为辅助治疗.
- 主要终点:运动障碍学会统一帕金森病评分表第三部分 (MDS-UPDRS-III) 24周总得分与基线的变化.
主要成果:
- 与安慰剂相比,阿皮卡在MDS-UPDRS-III得分上显示出统计学上显著的改善 (平均差异-2.2;p=0.010).
- 在阿皮卡和安慰剂组之间的新运动并发症发生率没有显著差异 (5.5%对比9.8%).
- 与研究药物相关的不良事件发生率在各组之间相似.
结论:
- 每天服用一次的阿皮卡耐受性很好,有效地改善了PD患者的运动严重程度,没有运动并发症.
- 在这种患者群体中,阿皮卡似乎不会诱导运动并发症的发展.
- 这些发现支持阿皮卡在治疗早期帕金森病的临床效用.
相关概念视频
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
119
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
119
01:15Parkinson's Disease: Overview
472
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
472
01:24Parkinson's Disease: Treatment
215
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
215
01:20Antiepileptic Drugs: Potassium Channel Activators
142
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
142
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
252
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
252
01:28Drug Therapy
37
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
37